An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK?
Anne Katrin Schlag
- Vol. 3, Iss: 1, pp 76-83
Reads0
Chats0
TLDR
Six countries that have been at the forefront of prescribing medical cannabis are looked at, including case studies of the three largest medical cannabis markets in the EU: Germany, Italy, and the Netherlands.Abstract:
This paper evaluates current regulatory regimes of medical cannabis using peer-reviewed and grey literature as well as personal communications. Despite the legalization of medical cannabis in the UK in November 2018, patients still lack access to the medicine, with fewer than 10 NHS prescriptions having been written to date. We look at six countries that have been at the forefront of prescribing medical cannabis, including case studies of the three largest medical cannabis markets in the EU: Germany, Italy, and the Netherlands. Canada, Israel and Australia add global examples. These countries have a more successful history of prescribing medical cannabis than the UK. Their legislations are outlined and numbers of medical cannabis prescriptions are provided to give an indication of how successful their regulatory regime has been in providing patient access. Evaluating countries' medical cannabis regulations allows us to offer implications for lessons to be learned for the development of a successful medical cannabis regime in the UK.read more
Citations
More filters
Journal ArticleDOI
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain.
Barbara Stella,Francesca Baratta,Carlo Della Pepa,Silvia Arpicco,Daniela Gastaldi,Franco Dosio +5 more
TL;DR: The most recent results from pharmaceutical companies and research groups investigating methods to improve cannabinoid bioavailability and to clearly establish its therapeutic efficacy, dose ranges, safety and also improve the patient compliance are presented in this article.
Journal ArticleDOI
Medical cannabis in the UK: From principle to practice.
Anne Katrin Schlag,David S. Baldwin,David S. Baldwin,Michael P. Barnes,Steve Bazire,Rachel Coathup,H. Valerie Curran,Rupert McShane,Lawrence D. Phillips,Ilina Singh,David J. Nutt +10 more
TL;DR: There is a need to maximise both clinical research and patient benefit, in a safe, cautious and ethical manner, so that those patients for whom cannabis is shown to be effective can access it.
Journal ArticleDOI
Cannabis based medicines and cannabis dependence: A critical review of issues and evidence.
Anne Katrin Schlag,Chandni Hindocha,Chandni Hindocha,Rayyan Zafar,David J. Nutt,H. Valerie Curran,H. Valerie Curran +6 more
TL;DR: In this article, the authors provide a review of the current research to determine if, how and to what extent, concerns about problems of dependence in recreational cannabis users apply to prescribed medical users.
Journal ArticleDOI
Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21.
TL;DR: The UK's first medical cannabis registry, T21 as discussed by the authors, was launched in August 2020 and reported the characteristics of the first patients enrolled in the registry, describing the health status of all patients enrolled into the project during its first 7 months of operation and the sociodemographic characteristics and primary presenting conditions for these patients, as well as details of the medical cannabis prescribed to these individuals.
Journal ArticleDOI
A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products
David J. Nutt,Lawrence D. Phillips,Michael P. Barnes,Brigitta Brander,Helen Valerie Curran,Alan Fayaz,David P. Finn,Tina Horsted,Julie Moltke,Chloe Sakal,Haggai Sharon,Saoirse E. O'Sullivan,Timothy Williams,Gregor Zorn,Anne Katrin Schlag +14 more
TL;DR: The benefit-safety profiles for cannabinoids were higher than for other commonly used medications for CNP largely because they contribute more to quality of life and have a more favorable side effect profile.
References
More filters
Journal ArticleDOI
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research
TL;DR: Despite increased cannabis use and a changing state-level policy landscape, conclusive evidence regarding the shortand long-term health effects—both harms and benefits—of cannabis use remains elusive.
Journal ArticleDOI
Availability and approval of cannabis‐based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation
TL;DR: There is considerable public and political interest in the use of cannabis products for medical purposes in Northern Ireland.
Journal ArticleDOI
Why medical cannabis is still out of patients' reach-an essay by David Nutt.
TL;DR: Cannabis has been used as a medicine for millennia, writes David Nutt, who charts its relatively recent prohibition, the effect on patients such as Billy Caldwell, and the failure of legal reform to make much difference.